Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
BörsenkürzelACOG
Name des UnternehmensAlpha Cognition Inc
IPO-datumJun 09, 2021
CEOMcfadden (Michael E)
Anzahl der mitarbeiter52
WertpapierartOrdinary Share
GeschäftsjahresendeJun 09
Addressec/o 1200 - 750 West Pender Street
StadtVANCOUVER
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV6C 2T8
Telefon16045649244
Websitehttps://www.alphacognition.com/
BörsenkürzelACOG
IPO-datumJun 09, 2021
CEOMcfadden (Michael E)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten